09:43 AM EST, 11/18/2024 (MT Newswires) -- Aclaris Therapeutics ( ACRS ) said Monday that it has acquired global development rights outside of China for potential anti-TSLP monoclonal and bispecific antibodies directed against both TSLP and IL4R developed by Chinese biotech firm Biosion.

The license agreement states that Biosion will receive more than $40 million in cash from Aclaris as an upfront license fee and reimbursement in exchange for its BSI-045B anti-thymic stromal lymphopoietin monoclonal antibody and its BSI-502 bispecific antibody.

Biosion will also receive 19.9% of Aclaris shares and is entitled for more than $900 million in further regulatory and sales milestone payments, as well as tiered royalty payments based on a low-to-mid single digit percentage of annual sales, the companies said.

Price: 2.3500, Change: 0.2900, Percent Change: +14.6341